Citadel Advisors
BLCM

Citadel Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Citadel Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,100
Closed -$14K – 10387
2019
Q4 		$14K Sell
1,100
-270
-20% -$2.49K ﹤0.01% 8985
2019
Q3 		$14K Buy
+1,370
New +$17.9K ﹤0.01% 9009
2018
Q3 		– Sell
-2,370
Closed -$175K – 9853
2018
Q2 		$175K Sell
2,370
-40
-2% -$3.12K ﹤0.01% 7987
2018
Q1 		$158K Sell
2,410
-620
-20% -$46.8K ﹤0.01% 7509
2017
Q4 		$255K Sell
3,030
-270
-8% -$26.5K ﹤0.01% 6715
2017
Q3 		$381K Buy
3,300
+720
+28% +$75.8K ﹤0.01% 5705
2017
Q2 		$301K Buy
2,580
+1,010
+64% +$125K ﹤0.01% 5906
2017
Q1 		$194K Buy
+1,570
New +$206K ﹤0.01% 6551
2016
Q1 		– Sell
-520
Closed -$105K – 8277
2015
Q4 		$105K Buy
520
+450
+643% +$80.5K ﹤0.01% 6626
2015
Q3 		$10K Sell
70
-150
-68% -$27.5K ﹤0.01% 8477
2015
Q2 		$47K Buy
220
+210
+2,100% +$51.5K ﹤0.01% 7692
2015
Q1 		$2K Buy
+10
New +$2.42K ﹤0.01% 8425

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's BLCM Position: Q3 2022 in Review

Citadel Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2022, closing a stake of 11,386 shares — an estimated $13K sold.

Citadel Advisors first reported a position in BLCM in Q4 2014 and held it in 22 quarters. The position peaked at $9.56M in Q2 2015. 28 funds tracked by Wall St. Rank hold BLCM as of Q3 2022.

  • Citadel Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 11,386 Bellicum Pharmaceuticals, Inc. shares in Q3 2022, an estimated $13K.
  • Citadel Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 22 quarters.
  • Citadel Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $9.56M in Q2 2015.
  • 28 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.